Press release
Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer
"Advanced Ovarian Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Ovarian Cancer Market.
The Advanced Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Ovarian Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Advanced Ovarian Cancer treatment therapies with a considerable amount of success over the years.
*
Advanced Ovarian Cancer companies working in the treatment market are Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others, are developing therapies for the Advanced Ovarian Cancer treatment
*
Emerging Advanced Ovarian Cancer therapies in the different phases of clinical trials are- DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others are expected to have a significant impact on the Advanced Ovarian Cancer market in the coming years.
*
In September 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage biopharmaceutical company focused on developing stenoparib (2X-121)-a unique dual PARP and WNT pathway inhibitor-announced that Dr. Jeremy Graff, President and Chief Development Officer, presented new and updated clinical data from its ongoing Phase 2 trial in advanced ovarian cancer patients. The presentation took place at the AACR 7th Biennial Special Conference on Ovarian Cancer, held September 19-21, 2025, at the Grand Hyatt Denver, Colorado. The poster is available in the Scientific Publications section of the company's website.
*
In September 2025, IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company advancing its DNA-mediated immunotherapy in Phase 3 development, announced new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001. This investigational gene-based interleukin-12 (IL-12) immunotherapy, developed using the company's proprietary TheraPlas Registered technology platform, is being evaluated for treating newly diagnosed advanced ovarian cancer. The findings were showcased in a presentation at the American Association for Cancer Research (AACR) Special Conference on Advances in Ovarian Cancer Research, held in Denver, Colorado.
*
In August 2025, According to a statement from Allarity Therapeutics, the U.S. FDA has granted Fast Track Designation to stenoparib, an investigational treatment for advanced ovarian cancer. This designation aims to expedite the development and review of therapies targeting serious conditions with significant unmet medical needs. It also allows for enhanced FDA interaction and may offer opportunities for accelerated approval, priority review, or rolling submissions if certain requirements are met.
*
In April 2025, Corcept Therapeutics announced that its pivotal Phase III ROSELLA trial evaluating oral relacorilant in combination with nab-paclitaxel met its primary endpoint by demonstrating improved progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. The study, which enrolled 381 patients across Argentina, Brazil, Canada, Europe, Australia, and South Korea, showed that the combination therapy reduced the risk of disease progression by 30% compared to treatment with nab-paclitaxel alone.
*
In March 2025, Imunon announced that the U.S. Food and Drug Administration (FDA) has agreed on the Phase III OVATION 3 trial protocol for IMNN-001 in ovarian cancer. IMNN-001, the company's lead investigational therapy, is being developed for women newly diagnosed with advanced ovarian cancer. The company is now initiating clinical trial sites and collaborating with investigators to begin patient enrollment.
*
In March 2025, AbbVie, a U.S.-based pharmaceutical company, announced the final results from its Phase III MIRASOL trial evaluating the antibody-drug conjugate (ADC) Elahere against chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This randomized study assessed the safety and efficacy of Elahere in women with folate receptor alpha (FR)-positive PROC.
*
In November 2024, IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company advancing its DNA-mediated immunotherapy, has announced new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, an investigational interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer developed using its proprietary TheraPlas Registered technology. The findings will be showcased in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
*
In August 2024, South Korean biopharmaceutical firm CanariaBio completed subject enrollment for its Phase II clinical trial evaluating oregovomab in combination with chemotherapy for advanced epithelial ovarian cancer. Known as FLORA-6, this double-blinded, placebo-controlled, multicenter study aims to assess the effectiveness of oregovomab alongside chemotherapy agents paclitaxel and carboplatin as a neo-adjuvant treatment for newly diagnosed patients.
*
In October 2024, Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company advancing a pipeline of innovative multifunctional biotherapeutics for challenging diseases, has announced the dosing of the first patient in its first-in-human Phase 1 trial (NCT06523803). This study aims to assess the safety and tolerability of the investigational therapy ZW171 for the treatment of advanced or metastatic ovarian cancer, non-small cell lung cancer (NSCLC), and other MSLN-expressing cancers
*
In May 2024, EVT801, a highly selective small-molecule VEGFR3 TKI, demonstrated good tolerability in patients with advanced solid tumors, with a 46% stable disease rate observed in advanced ovarian cancer patients, as reported in a Phase 1 trial (NCT05114668).
Advanced Ovarian Cancer Overview
Advanced ovarian cancer refers to ovarian cancer that has spread beyond the ovaries to other parts of the pelvis, abdomen, or distant organs. It is typically classified as Stage III or IV, depending on the extent of spread. Symptoms may be vague, such as bloating, abdominal pain, early satiety, or urinary changes, which often leads to late diagnosis. Treatment usually involves a combination of surgery to remove as much of the tumor as possible (debulking) and chemotherapy, sometimes alongside targeted therapies or immunotherapy. Prognosis depends on factors like stage at diagnosis, tumor type, and response to treatment.
Get a Free Sample PDF Report to know more about Advanced Ovarian Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight [https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Advanced Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:
*
DS-6000a: Daiichi Sankyo, Inc
*
AMG-794: Amgen
*
COM701: Compugen Ltd
*
NC762: NextCure
*
SON-1010: Sonnet BioTherapeutics
*
SOT101: SOTIO Biotech B.V.
*
AK112: Akeso
*
2X-121: Allarity Therapeutics
*
Pembrolizumab: Merck Sharp & Dohme
*
Oregovomab: CanariaBio Inc.
*
Stenoparib: Allarity Therapeutics
*
DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Ovarian Cancer Route of Administration
Advanced Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical.
Advanced Ovarian Cancer Molecule Type
Advanced Ovarian Cancer Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
*
Advanced Ovarian Cancer Assessment by Product Type
*
Advanced Ovarian Cancer By Stage and Product Type
*
Advanced Ovarian Cancer Assessment by Route of Administration
*
Advanced Ovarian Cancer By Stage and Route of Administration
*
Advanced Ovarian Cancer Assessment by Molecule Type
*
Advanced Ovarian Cancer by Stage and Molecule Type
DelveInsight's Advanced Ovarian Cancer Report covers around 50+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Advanced Ovarian Cancer product details are provided in the report. Download the Advanced Ovarian Cancer pipeline report to learn more about the emerging Advanced Ovarian Cancer therapies [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Advanced Ovarian Cancer Therapeutics Market include:
Key companies developing therapies for Advanced Ovarian Cancer are - Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Advanced Ovarian Cancer Pipeline Analysis:
The Advanced Ovarian Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment.
*
Advanced Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Ovarian Cancer drugs and therapies [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Ovarian Cancer Pipeline Market Drivers
*
Increasing prevalence of Advanced Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Advanced Ovarian Cancer Market.
Advanced Ovarian Cancer Pipeline Market Barriers
*
However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Advanced Ovarian Cancer Market growth.
Scope of Advanced Ovarian Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Advanced Ovarian Cancer Companies: Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others
*
Key Advanced Ovarian Cancer Therapies: DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others
*
Advanced Ovarian Cancer Therapeutic Assessment: Advanced Ovarian Cancer current marketed and Advanced Ovarian Cancer emerging therapies
*
Advanced Ovarian Cancer Market Dynamics: Advanced Ovarian Cancer market drivers and Advanced Ovarian Cancer market barriers
Request for Sample PDF Report for Advanced Ovarian Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Advanced Ovarian Cancer Report Introduction
2. Advanced Ovarian Cancer Executive Summary
3. Advanced Ovarian Cancer Overview
4. Advanced Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Advanced Ovarian Cancer Pipeline Therapeutics
6. Advanced Ovarian Cancer Late Stage Products (Phase II/III)
7. Advanced Ovarian Cancer Mid Stage Products (Phase II)
8. Advanced Ovarian Cancer Early Stage Products (Phase I)
9. Advanced Ovarian Cancer Preclinical Stage Products
10. Advanced Ovarian Cancer Therapeutics Assessment
11. Advanced Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Ovarian Cancer Key Companies
14. Advanced Ovarian Cancer Key Products
15. Advanced Ovarian Cancer Unmet Needs
16 . Advanced Ovarian Cancer Market Drivers and Barriers
17. Advanced Ovarian Cancer Future Perspectives and Conclusion
18. Advanced Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-ovarian-cancer-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-pfizer-daiichi-sankyo-astellas-pharma-jiangsu-hengrui-boehringer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer here
News-ID: 4225932 • Views: …
More Releases from ABNewswire
Forget AskJeeves, AskAI Free Is Here
AskAI Free is a new online platform offering free access to multiple AI tools for everyday and professional use. Users can chat with models like ChatGPT 4o, Claude Sonnet 4, and Gemini 2.0 Flash, or get help from specialized assistants such as the AI Lawyer and Dating AI Coach. No registration or payment is required. The site focuses on clarity, privacy, and accessibility, helping users find fast, reliable answers across…
Improve Cybersecurity Risk Management with IBN Technologies to Protect Critical …
IBN Technologies delivers advanced cybersecurity risk management strategies, helping organizations identify vulnerabilities, prioritize risks, and implement robust protection measures. This news outlines practical approaches for improving security posture, ensuring regulatory compliance, and safeguarding critical digital assets against emerging cyber threats.
As cyber threats continue to evolve in complexity and frequency, organizations are under mounting pressure to safeguard sensitive data, maintain compliance, and ensure uninterrupted operations. Cybersecurity risk management [https://www.ibntech.com/microsoft-security-services/] has become…
U.S. Firms Outsource Payroll Services to IBN Tech for Expert Payroll Management
As payroll demands grow complex, U.S. businesses turn to IBN Technologies for expert payroll outsourcing. With 99% accuracy, cost savings up to 20%, and strong compliance management, IBN simplifies payroll across multi-state operations. From tax filings to secure employee access, its tailored payroll solutions reduce risks, free up internal teams, and improve operational efficiency.
Many organizations are using third-party payroll systems as workforces and legal needs evolve. Payroll administration that satisfies…
IBN Technologies Cyber Security Consulting Services Strengthen Enterprise Securi …
With cyber threats growing in volume and sophistication, IBN Tech offers specialized Cyber Security Consulting Services to help USA businesses identify vulnerabilities, reinforce security measures, and implement proactive strategies. Their services include vulnerability assessment, SOC & SIEM consulting, MDR, vCISO advisory, and cloud security, ensuring compliance, operational resilience, and long-term digital protection.
With cyber threats growing in both volume and sophistication, organizations across industries are facing unparalleled challenges in securing their…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
